# A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis

> **NCT05630547** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 174 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** SAR443820
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05630547
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-19
- **Primary completion:** 2024-11-21
- **Final completion:** 2024-11-21
- **Target enrollment:** 174 (ACTUAL)
- **Why stopped:** The study was terminated as it did not meet its primary and key secondary endpoints
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05630547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05630547, "A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05630547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*